News
REGN
964.28
-0.21%
-2.03
Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Regeneron Pharmaceuticals, Inc.'s Eylea HD reinforces its market dominance in treating wet AMD. The drug is a blockbuster drug for the treatment of wet age-related macular degeneration. The company's Libtayo's revenue growth is expected to become a blockbuster. Regeneron benefits financially from Dupixent sales and a strong balance sheet. I recommend buying Regeneron shares due to diversified product strength and pipeline potential.
Seeking Alpha · 1d ago
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
NASDAQ · 2d ago
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
12 analysts have expressed a variety of opinions on Regeneron Pharmaceuticals (NASDAQ:REGN) over the past quarter. The analysts have established 12-month price targets for the company of $1068.58. The company has an average target of $1184.00 for the next 12 months. Regeneron pharmaceuticals discovers, develops, and commercializes products that fight eye disease.
Benzinga · 2d ago
Regeneron Pharma Is Maintained at Buy by Truist Securities
Dow Jones · 2d ago
Regeneron Pharma Price Target Maintained With a $1135.00/Share by Truist Securities
Dow Jones · 2d ago
REGN Quantitative Stock Analysis - Benjamin Graham
NASDAQ · 2d ago
Truist Financial Remains a Buy on Regeneron (REGN)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Regeneron (REGN) and Intuitive Surgical (ISRG)
United Therapeutics, Regeneron and Intuitive Surgical are among the top 3 Healthcare stocks recommended by analysts. 3 analysts have issued bullish reports on the stocks. Wells Fargo, Bernstein and Stifel Nicolaus have each assigned a Buy rating to the companies. The analysts are bullish on the Healthcare sector.
TipRanks · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
Dow Jones Industrial Average was down 0.36% on Monday. Top three S&P 500 percentage gainers: Super Micro Computer, Micron Technology, Navios Maritime. Wall Street's main indexes eased at the start of the holiday-shortened week. Advancing chip stocks kept losses on the tech-heavy Nasdaq in check.
Reuters · 2d ago
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC) and Regeneron (REGN)
TipRanks · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Wall Street's main indexes open lower on Monday. Dow Jones Industrial Average was down 0.26% at 39,373.11. Boeing gained after the planemaker said its CEO would be stepping down. Landos Biopharma, Foot Locker, US energy sector rise.
Reuters · 2d ago
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
The FDA issued a complete response letter to Regeneron Pharmaceuticals Inc’s application for odronextamab. The drug is being developed as a blood cancer treatment. The FDA said it needs more data from the company to confirm the safety and efficacy of the drug. Regeneron has been actively enrolling patients in multiple Phase 3 trials for the treatment.
Benzinga · 2d ago
Stocks End Lower as Hawkish Fed Comments Push Bond Yields Higher
The S&P 500 Index closed down -0.31% on Monday. Some hawkish Fed comments pushed T-note yields higher and undercut stocks. Negative corporate news also weighed on the broader market. Take-Two Interactive Software closed down more than -6% after Grand Theft Auto VI production could miss release window. United Airlines Holdings closed down on reports of possible airline sanctions.
Barchart · 3d ago
FDA declines to approve Regeneron lymphoma drug odronextamab
FDA declines to approve Regeneron lymphoma drug odronextamab for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. The FDA cites the enrollment status of confirmatory trials. The drug is also being reviewed by European regulators for the treatment of both indications.
Seeking Alpha · 3d ago
BUZZ-Regeneron falls after FDA declines to approve its blood cancer therapy
Regeneron Pharmaceuticals shares fall 1.7% to $951 premarket. Company says FDA declines to approve its blood cancer therapy for two forms of lymphoma. FDA raised concerns over progress of ongoing confirmatory trials. Stock up 18% in the last 12 months.
Reuters · 3d ago
Regeneron Says FDA Rejects BLA Approval For Odronextamab In Follicular Lyphoma
NASDAQ · 3d ago
FDA Rejects Regeneron's Odronextamab in Follicular, Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals says the FDA has turned away its application for approval of odronextamab. The company was seeking approval to treat two most common subtypes of non-Hodgkin lymphoma. Company says only approvability issue is enrollment status of confirmatory trials.
Dow Jones · 3d ago
US FDA declines to approve Regeneron's blood cancer therapy
US FDA declines to approve Regeneron's blood cancer therapy for two most common subtypes of -Hodgkin lymphoma. Issue related to the enrollment status of the confirmatory trials, company says. Regeneron Pharmaceuticals says the drug is not approved for treatment of cancer.
Reuters · 3d ago
Stocks Slip on Corporate News and Hawkish Fed Comments
Take-Two Interactive Software is down more than -6% after Grand Theft Auto VI production could miss its 2025 release window. United Airlines Holdings is down -4% on a report that the FAA is considering sanctions on the company. T-note yields pushed higher on hawkish Fed comments. Atlanta Fed President Bostic said he expects only one 25 bp rate cut this year. Super Micro Computer is up more than +9% after JPMorgan upgrades the stock.
Barchart · 3d ago
Weekly Report: what happened at REGN last week (0318-0322)?
Weekly Report · 3d ago
More
Webull provides a variety of real-time REGN stock news. You can receive the latest news about Regeneron Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others.